Friederike A G Meyer-Wentrup
Overview
Explore the profile of Friederike A G Meyer-Wentrup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kroeze E, Kleisman M, Kester L, Scheijde-Vermeulen M, Sonneveld E, Buijs-Gladdines J, et al.
Hemasphere
. 2024 Jul;
8(7):e117.
PMID: 38948925
Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these...
2.
Scheijde-Vermeulen M, Kester L, Westera L, Tops B, Meyer-Wentrup F
Lab Invest
. 2023 Oct;
104(1):100267.
PMID: 37898291
The study was conducted to assess the feasibility of integrating state-of-the-art sequencing techniques and flow cytometry into diagnostic workup of pediatric lymphoma. RNA sequencing (RNAseq), whole exome sequencing, and flow...
3.
Schulpen M, Beishuizen A, Chamuleau M, Dinmohamed A, Meyer-Wentrup F, Vormoor H, et al.
Haematologica
. 2023 Aug;
109(3):936-941.
PMID: 37646666
No abstract available.
4.
Zijtregtop E, Winterswijk L, Beishuizen T, Zwaan C, Nievelstein R, Meyer-Wentrup F, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831520
While cervical lymphadenopathy is common in children, a decision model for detecting high-grade lymphoma is lacking. Previously reported individual lymphoma-predicting factors and multivariate models were not sufficiently discriminative for clinical...
5.
Zijtregtop E, Diez C, Zwaan C, Veening M, Beishuizen A, Meyer-Wentrup F
Br J Haematol
. 2022 Sep;
200(1):70-78.
PMID: 36128637
Classical Hodgkin lymphoma (cHL) is characterised by malignant Hodgkin Reed-Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active cross-talk between malignant and non-malignant cells. One promising biomarker...
6.
Zijtregtop E, Tromp I, Dandis R, Zwaan C, Lam K, Meyer-Wentrup F, et al.
Pathol Oncol Res
. 2022 Aug;
28:1610482.
PMID: 36032657
Immunohistochemical markers are associated with treatment outcome in adults with classical Hodgkin Lymphoma (cHL). Studies in children are scarce and inconsistent. We investigated in 67 children with cHL, whether the...
7.
Greve P, Meyer-Wentrup F, Peperzak V, Boes M
Immunother Adv
. 2022 Aug;
1(1):ltab001.
PMID: 35919738
After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric...
8.
van den Bosch C, Spijkerman J, Wijnen M, Kremer Hovinga I, Meyer-Wentrup F, van der Steeg A, et al.
Support Care Cancer
. 2022 Jul;
30(10):8069-8079.
PMID: 35776186
Purpose: The purpose of this study was to determine the most optimal central venous catheter (CVC) for pediatric patients with Hodgkin lymphoma (HL) in terms of complications. Methods: A retrospective...
9.
Hanemaaijer E, Margaritis T, Sanders K, Bos F, Candelli T, Al-Saati H, et al.
Proc Natl Acad Sci U S A
. 2021 Jan;
118(5).
PMID: 33500353
Neuroblastoma is the most common extracranial solid tumor and accounts for ∼10% of pediatric cancer-related deaths. The exact cell of origin has yet to be elucidated, but it is generally...
10.
Reedijk A, Zijtregtop E, Coebergh J, Meyer-Wentrup F, Hebeda K, Zwaan C, et al.
Br J Haematol
. 2020 Feb;
189(6):1093-1106.
PMID: 32030738
Population-based studies that assess long-term patterns of incidence, major aspects of treatment and survival are virtually lacking for Hodgkin lymphoma (HL) at a younger age. This study assessed the progress...